VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | PROOF 301: infigratinib in advanced CCA

Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, outlines the rationale and trial design of PROOF 301 (NCT03773302), a Phase III study investigating first line infigratinib in cholangiocarcinoma (CCA) patients with FGFR2 gene fusions/translocations. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter